Canadian Guidelines for Hyperlipidemia Management
Primary Treatment Targets
- The Canadian Cardiovascular Society recommends an optimal LDL-C level of ≤2.0 mmol/L as the primary treatment target, with non-HDL-C ≤2.6 mmol/L and apolipoprotein B ≤80 mg/dL as alternative targets supported by strong evidence 1
- LDL-C remains the primary goal of therapy at ≤2.0 mmol/L, which is more aggressive than the U.S. NCEP ATP III goal of <100 mg/dL for high-risk patients 1, 2
Alternative Treatment Targets
- Non-HDL-C ≤2.6 mmol/L is an alternative target with strong evidence, particularly useful when triglycerides are elevated ≥200 mg/dL 1, 3, 4
- Apolipoprotein B ≤80 mg/dL is another alternative target with strong evidence 1
Risk Stratification Approach
- The Canadian guidelines use the Framingham Risk Score (FRS) to estimate 10-year total ASCVD risk, and double the FRS if family history of premature ASCVD exists in first-degree relatives 1
- Patients are categorized as low-risk, intermediate-risk (FRS 5-19%), or high-risk, to guide treatment intensity 1
Secondary Risk Assessment
- For intermediate-risk patients, consider additional testing such as lipoprotein(a) levels, high-sensitivity C-reactive protein, coronary calcium scoring, and ankle-brachial index 1
Treatment Implementation
- Statins are first-line pharmacological therapy for LDL-C lowering, with lifestyle modifications as the initial step 2
- The treatment algorithm includes initiating lifestyle modifications, adding statin therapy if targets are not met, and considering combination therapy with fibrates for patients with low HDL and elevated triglycerides 2, 3, 4
HDL and Triglyceride Goals
- Triglycerides <150 mg/dL and HDL cholesterol >40 mg/dL are secondary targets, with an HDL goal 10 mg/dL higher for women 2